MCID: SKN019
MIFTS: 68

Skin Melanoma

Categories: Cancer diseases, Ear diseases, Skin diseases

Aliases & Classifications for Skin Melanoma

MalaCards integrated aliases for Skin Melanoma:

Name: Skin Melanoma 12 54 15
Cutaneous Melanoma 12 15 71
Malignant Melanoma of Ear and/or External Auricular Canal 12
Malignant Melanoma of Skin of Trunk Except Scrotum 12
Malignant Melanoma of Skin of Lower Limb 12
Malignant Melanoma of Skin of Upper Limb 12
Melanoma, Cutaneous Malignant 43
Malignant Lower Limb Melanoma 12
Malignant Upper Limb Melanoma 12
Malignant Scalp Melanoma 12
Malignant Trunk Melanoma 12
Malignant Neck Melanoma 12
Malignant Ear Melanoma 12
Malignant Lip Melanoma 12
Melanoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:8923
ICD9CM 34 172 172.9
MeSH 43 C562393
NCIt 49 C3510
SNOMED-CT 67 93655004
ICD10 32 C43 C43.9
UMLS 71 C0025202 C0151779

Summaries for Skin Melanoma

Disease Ontology : 12 A skin cancer that has material basis in melanocytes.

MalaCards based summary : Skin Melanoma, also known as cutaneous melanoma, is related to melanoma, cutaneous malignant 1 and skin carcinoma, and has symptoms including pruritus and exanthema. An important gene associated with Skin Melanoma is LINC00937 (Long Intergenic Non-Protein Coding RNA 937), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Isotretinoin and Vindesine have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and lung, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Skin Melanoma

Diseases related to Skin Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 483)
# Related Disease Score Top Affiliating Genes
1 melanoma, cutaneous malignant 1 34.4 TYR TP53 PMEL NRAS MITF MDM2
2 skin carcinoma 33.2 TYR TP53 NRAS CDKN2A CASP3
3 acral lentiginous melanoma 33.0 NRAS CDKN2A BRAF
4 amelanotic melanoma 32.9 TYR MITF BRAF
5 melanoma in congenital melanocytic nevus 32.8 PMEL NRAS BRAF
6 lentigo maligna melanoma 31.8 MMP9 MMP2 MITF
7 mucosal melanoma 31.4 NRAS MITF CDKN2A BRAF
8 familial retinoblastoma 31.2 TP53 MDM2 CDKN2A
9 keratosis 31.2 TP53 MMP9 MMP2 CDKN2A
10 thyroid carcinoma 31.1 TP53 NRAS BRAF
11 vitiligo-associated multiple autoimmune disease susceptibility 1 31.1 TYR PMEL MITF FGF2
12 spitz nevus 31.1 TP53 CDKN2A BRAF
13 retinoblastoma 31.0 TP53 MDM2 CDKN2B CDKN2A CASP3
14 melanoma 31.0 TYR TP53 PMEL NRAS MMP2 MITF
15 ocular melanoma 30.9 NRAS CDKN2A CASP3
16 li-fraumeni syndrome 30.8 TP53 MDM2 ERBB2 CDKN2A
17 actinic keratosis 30.8 TYR TP53 MMP9 MMP2 MITF CDKN2B
18 lymphoma, non-hodgkin, familial 30.7 TP53 NRAS MDM2 CDKN2B CASP3 BRAF
19 nodular malignant melanoma 30.7 TYR TP53 NRAS MITF CDKN2A BRAF
20 b-cell lymphoma 30.7 TP53 MDM2 CDKN2B CDKN2A CASP3
21 connective tissue cancer 30.7 TP53 MDM2 CDKN2A CASP3
22 in situ carcinoma 30.6 TP53 ERBB2 CDKN2A
23 meningioma, familial 30.6 TP53 MMP9 MDM2 ERBB2 CDKN2B CDKN2A
24 halo nevi 30.6 TYR PMEL
25 actinic cheilitis 30.6 TP53 MDM2
26 lip cancer 30.6 TP53 MDM2 BRAF
27 epithelioid cell melanoma 30.6 TYR MITF
28 squamous cell carcinoma 30.6 TP53 MMP9 MMP2 IGF1R ERBB2 CDKN2A
29 vascular cancer 30.6 TP53 MITF FGF2
30 neurofibroma 30.5 TYR TP53 MITF CDKN2A
31 cheilitis 30.5 TP53 MMP9 MDM2
32 basal cell carcinoma 30.5 TYR TP53 MMP9 MMP2 MDM2 FGF2
33 skin squamous cell carcinoma 30.5 TP53 NRAS CDKN2A BRAF
34 gastrointestinal stromal tumor 30.5 TP53 MMP9 MMP2 ERBB2 CDKN2A CASP3
35 endometrial adenocarcinoma 30.5 TP53 FGF2 ERBB2 CDKN2A
36 osteogenic sarcoma 30.5 TP53 MMP2 MDM2 IGF1R CDKN2A CASP3
37 fibrosarcoma 30.4 TP53 MMP9 MMP2 FGF2
38 oligodendroglioma 30.4 TP53 MDM2 CDKN2B CDKN2A
39 leukemia, chronic lymphocytic 30.4 TP53 NRAS MDM2 ERBB2 CDKN2B CDKN2A
40 papilloma 30.4 TP53 CDKN2B CDKN2A CASP3
41 liposarcoma 30.4 TP53 MDM2 IGF1R CDKN2A CASP3
42 ductal carcinoma in situ 30.3 TP53 MMP9 IGF1R ERBB2 CDKN2A
43 pancreatic cancer 30.3 TP53 MMP9 MMP2 IGF1R FGF2 ERBB2
44 grade iii astrocytoma 30.3 TP53 MMP9 MMP2 MDM2 CDKN2B CDKN2A
45 lymphoma 30.3 TP53 NRAS MDM2 IGF1R CDKN2B CDKN2A
46 glioma 30.3 TP53 MMP9 MMP2 MDM2 FGF2 ERBB2
47 oculocutaneous albinism 30.2 TYR PMEL MITF
48 neuroblastoma 30.2 TYR TP53 NRAS MMP9 MMP2 MDM2
49 brain cancer 30.2 TP53 NRAS MDM2 FGF2 CDKN2B CASP3
50 adenocarcinoma 30.2 TP53 MMP9 MMP2 MDM2 IGF1R ERBB2

Graphical network of the top 20 diseases related to Skin Melanoma:



Diseases related to Skin Melanoma

Symptoms & Phenotypes for Skin Melanoma

UMLS symptoms related to Skin Melanoma:


pruritus, exanthema

MGI Mouse Phenotypes related to Skin Melanoma:

45 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.47 BRAF CASP3 CDKN2A ERBB2 FGF2 IGF1R
2 homeostasis/metabolism MP:0005376 10.45 BRAF CASP3 CDKN2A CDKN2B ERBB2 FGF2
3 cardiovascular system MP:0005385 10.43 BRAF CASP3 CDKN2A ERBB2 FGF2 IGF1R
4 cellular MP:0005384 10.42 BRAF CASP3 CDKN2A CDKN2B ERBB2 FGF2
5 hematopoietic system MP:0005397 10.4 BRAF CASP3 CDKN2A CDKN2B FGF2 IGF1R
6 integument MP:0010771 10.37 BRAF CASP3 CDKN2A CDKN2B ERBB2 IGF1R
7 endocrine/exocrine gland MP:0005379 10.36 BRAF CASP3 CDKN2A CDKN2B ERBB2 IGF1R
8 growth/size/body region MP:0005378 10.35 BRAF CASP3 CDKN2A ERBB2 IGF1R MDM2
9 immune system MP:0005387 10.35 BRAF CASP3 CDKN2A CDKN2B IGF1R MCAM
10 mortality/aging MP:0010768 10.34 BRAF CASP3 CDKN2A CDKN2B ERBB2 FGF2
11 craniofacial MP:0005382 10.3 BRAF CASP3 ERBB2 IGF1R MDM2 MITF
12 digestive/alimentary MP:0005381 10.25 BRAF CASP3 CDKN2A ERBB2 IGF1R MDM2
13 embryo MP:0005380 10.24 BRAF CDKN2A ERBB2 IGF1R MDM2 MITF
14 neoplasm MP:0002006 10.23 BRAF CDKN2A CDKN2B ERBB2 FGF2 IGF1R
15 nervous system MP:0003631 10.21 BRAF CASP3 CDKN2A ERBB2 FGF2 IGF1R
16 muscle MP:0005369 10.18 BRAF CASP3 CDKN2A ERBB2 FGF2 IGF1R
17 limbs/digits/tail MP:0005371 10.16 BRAF ERBB2 IGF1R MDM2 MITF MMP9
18 hearing/vestibular/ear MP:0005377 10.11 BRAF CASP3 FGF2 IGF1R MITF TP53
19 no phenotypic analysis MP:0003012 10.1 CASP3 CDKN2A CDKN2B MCAM MDM2 MITF
20 reproductive system MP:0005389 10.03 BRAF CASP3 CDKN2A CDKN2B ERBB2 FGF2
21 pigmentation MP:0001186 10.02 BRAF CASP3 CDKN2A MDM2 MITF NRAS
22 renal/urinary system MP:0005367 9.92 BRAF CASP3 CDKN2B MDM2 MITF MMP9
23 skeleton MP:0005390 9.8 BRAF CASP3 CDKN2A ERBB2 FGF2 IGF1R
24 respiratory system MP:0005388 9.76 BRAF CASP3 CDKN2A ERBB2 IGF1R MMP2
25 vision/eye MP:0005391 9.36 BRAF CASP3 CDKN2A FGF2 MITF MMP2

Drugs & Therapeutics for Skin Melanoma

Drugs for Skin Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 659)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
2
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
3
Pravastatin Approved Phase 4 81093-37-0 54687
4
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
5
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
6
Infliximab Approved Phase 4 170277-31-3
7
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
8
Citalopram Approved Phase 4 59729-33-8 2771
9
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Aminolevulinic acid Approved Phase 4 106-60-5 137
12
Cabergoline Approved Phase 4 81409-90-7 54746
13
Menthol Approved Phase 4 2216-51-5 16666
14
Etanercept Approved, Investigational Phase 4 185243-69-0
15
Tofacitinib Approved, Investigational Phase 4 477600-75-2
16
Adalimumab Approved Phase 4 331731-18-1 16219006
17
Crizotinib Approved Phase 4 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
18
Palbociclib Approved, Investigational Phase 4 571190-30-2 5005498 5330286 11431660
19
Olaparib Approved Phase 4 763113-22-0 23725625
20
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
21
Ceritinib Approved Phase 4 1032900-25-6
22
ramucirumab Approved, Investigational Phase 4 947687-13-0
23
Bortezomib Approved, Investigational Phase 4 179324-69-7 93860 387447
24
Lapatinib Approved, Investigational Phase 4 231277-92-2, 388082-78-8 208908 9941095
25
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
26
Sunitinib Approved, Investigational Phase 4 557795-19-4, 341031-54-7 5329102
27
Lactitol Investigational Phase 4 585-88-6, 585-86-4 493591
28
Epicatechin Investigational Phase 4 35323-91-2, 490-46-0 72276
29
Theobromine Investigational Phase 4 83-67-0 5429
30 Keratolytic Agents Phase 4
31 Salicylates Phase 4
32 Gastrointestinal Agents Phase 4
33 Cyclosporins Phase 4
34 Psychotropic Drugs Phase 4
35 Antidepressive Agents Phase 4
36 Fibrin Tissue Adhesive Phase 4
37 Coagulants Phase 4
38 Serotonin Agents Phase 4
39 Parasympatholytics Phase 4
40 Serotonin Uptake Inhibitors Phase 4
41 Cholinergic Agents Phase 4
42 Muscarinic Antagonists Phase 4
43 Cholinergic Antagonists Phase 4
44 Viscosupplements Phase 4
45 Monoamine Oxidase Inhibitors Phase 4
46 Dermatologic Agents Phase 4
47 Photosensitizing Agents Phase 4
48 Antiparkinson Agents Phase 4
49 Methyl 5-aminolevulinate Phase 4
50 Dopamine agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 2932)
# Name Status NCT ID Phase Drugs
1 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
2 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Unknown status NCT02626065 Phase 4 Nivolumab
3 A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma Unknown status NCT00540930 Phase 4 Ranibizumab
4 Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
5 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
6 Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
7 An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa. Completed NCT01898585 Phase 4 Zelboraf
8 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
9 A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
10 Can Fibrin Sealant be Used to Reduce Post-operative Drainage Following Lymph Node Dissection: a Prospective Randomised Double Blind Trial. Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
11 A Randomized Control Trial for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection Completed NCT02476357 Phase 4
12 IL-2 Neuropsychiatric Symptoms: Mechanism and Prevention Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
13 Photodynamic Therapy for Melanoma Precursor Lesion Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion (BF-200 ALA) as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
14 An Open-Label Study Using the MedPulser Electroporation System to Treat Cutaneous and Subcutaneous Foci of Cancer Completed NCT00198276 Phase 4
15 Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
16 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
17 A Prospective, Randomized Trial Comparing Surgery Versus Radiosurgery for the Treatment of Metastatic Brain Tumors Completed NCT00075166 Phase 4
18 Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease. Completed NCT00640159 Phase 4 Zelapar
19 An Evaluation of the Efficacy of the Tumor Necrosis Factor-alpha Antagonist Infliximab in Treatment Resistant Major Depression: Mechanisms and Mediators Completed NCT00463580 Phase 4 Infliximab;Placebo
20 A Comparison of Polyglactin 910 and Chromic Gut Suture in the Closure of Punch Biopsy Sites Completed NCT01722994 Phase 4
21 Neoadjuvant GM-CSF Treatment and Modulation of Immune Cell Profile of the SLN in Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
22 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
23 A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects With Unresectable or Metastatic Melanoma or PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) in India (Keynote-593) Recruiting NCT03715205 Phase 4 Pembrolizumab
24 Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial Recruiting NCT03673332 Phase 4 immune-checkpoint inhibitors therapies
25 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
26 A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy Recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
27 Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease: a Multicenter Randomized Controlled Trial Recruiting NCT03909646 Phase 4 Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram;5Fluorouracil
28 Phase IV Ipilimumab in Melanoma: A National, Multicenter, Interventional Study in Patients With Unresectable or Metastatic Melanoma Active, not recruiting NCT02068196 Phase 4 Ipilimumab
29 PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS Active, not recruiting NCT02092467 Phase 4 tofacitinib;tofacitinib
30 COcoa Supplement and Multivitamin Outcomes Study Active, not recruiting NCT02422745 Phase 4
31 Influenza Vaccine Responses in the Setting of Melanoma Treatment Enrolling by invitation NCT03315975 Phase 4
32 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
33 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting Programmed Cell Death 1 (PD-1) Not yet recruiting NCT03313544 Phase 4 Nivolumab
34 Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
35 A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
36 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
37 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
38 Randomized, Comparative Phase II/III Study Between Treatment With CSF470 Vaccine (Allogeneic, Irradiated) Plus BCG and MOLGRAMOSTIN (rhGM-CSF) as Adjuvants and Interferon-alfa 2b (IFN-ALPHA), in Stages IIB, IIC and III Post Surgery Cutaneous Melanoma Patients Unknown status NCT01729663 Phase 2, Phase 3 interferon alpha 2b
39 Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination: Post-Operative Adjuvant Ganglioside GM2-KLH/QS-21 (BMS-248479) Vaccination Treatment After Resection of Primary Cutaneous Melanoma Thicker Than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-Arm Multicenter Randomized Phase III Trial vs. Observation Unknown status NCT00005052 Phase 3
40 A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Plus BCG Versus Placebo Plus BCG as a Post-Surgical Treatment for Stage IV Melanoma Unknown status NCT00052156 Phase 3
41 Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma Unknown status NCT00052130 Phase 3
42 Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts Unknown status NCT00002455 Phase 3
43 PHASE III TRIAL OF MELACINE PLUS INTERFERON ALFA-2B VERSUS INTERFERON ALFA-2B IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA Unknown status NCT00002767 Phase 3
44 Treatment Of Radiation Retinopathy Trial Subtitle: Treatment of Radiation Retinopathy; Influence of Lucentis® and Kenalog® on Radiation Retinopathy After Irradiation of Choroidal Melanoma. Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
45 POST-OPERATIVE ADJUVANT INTERFERON-ALFA-2B (INTRON-A) TREATMENT AFTER RESECTION OF THICK PRIMARY MELANOMA AND/OR REGIONAL LYMPHNODE METASTASES 'INTERMEDIATE-HIGH DOSE' VS INTERMEDIATE-LOW DOSE' IFN-ALFA VS OBSERVATION: A 3-ARM MULTICENTER RANDOMIZED PHASE III TRIAL Unknown status NCT00002763 Phase 3
46 Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients Unknown status NCT01861938 Phase 2, Phase 3
47 PEG-Intron Observation After Regional Lymph Node Dissection in AJCC Stage III (TxN1-2MO) Melanoma Patients: a Randomized Phase III Trial Unknown status NCT00006249 Phase 3
48 A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients Unknown status NCT02938299 Phase 3 L19IL2 + L19TNF
49 A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Melanoma With Hepatic Metastasis Unknown status NCT00039234 Phase 3 histamine dihydrochloride
50 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3

Search NIH Clinical Center for Skin Melanoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
Carmustine
dabrafenib
Dacarbazine
docetaxel
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Lomustine
peginterferon alfa-2a
peginterferon alfa-2b
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b
temozolomide
trametinib
Vemurafenib

Cochrane evidence based reviews: melanoma, cutaneous malignant

Genetic Tests for Skin Melanoma

Anatomical Context for Skin Melanoma

MalaCards organs/tissues related to Skin Melanoma:

40
Skin, Lymph Node, Lung, T Cells, Brain, Breast, Testes

Publications for Skin Melanoma

Articles related to Skin Melanoma:

(show top 50) (show all 7241)
# Title Authors PMID Year
1
Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15. 54 61
15960923 2005
2
The loss of NM23 protein in malignant melanoma predicts lymphatic spread without affecting survival. 54 61
11268486 2000
3
Differential expression of nm23 H-1 protein in conjunctival melanoma and potential precursor lesions. 61 54
10620396 1999
4
[Prognosis and invasion marker expression of cutaneous melanoma. Metastasis-associated genes (nm23, CD44v3, MMP2]. 61 54
10064977 1999
5
Association between NM23-H1 gene expression and metastasis of human uveal melanoma in an animal model. 61 54
8843913 1996
6
Surgical Management of Primary Cutaneous Melanoma. 61
31753116 2020
7
Principles of Targeted Therapy for Melanoma. 61
31753111 2020
8
MCM7 silencing promotes cutaneous melanoma cell autophagy and apoptosis by inactivating the AKT1/mTOR signaling pathway. 61
31535400 2020
9
Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of cutaneous melanoma. 61
31240705 2020
10
Induction of G0/G1 phase arrest and apoptosis by CRISPR/Cas9-mediated knockout of CDK2 in A375 melanocytes. 61
31832188 2020
11
Learning a Latent Space of Highly Multidimensional Cancer Data. 61
31797612 2020
12
Melanoma in older patients: declining gap in survival between younger and older patients with melanoma. 61
31347929 2020
13
A variant in FTO gene shows association with histological ulceration in cutaneous melanoma. 61
31469442 2020
14
Risk factors for post-operative complications after sentinel lymph node biopsy for cutaneous melanoma: Results from a large cohort study. 61
31607594 2019
15
Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. 61
31570567 2019
16
LncRNA FOXD3-AS1 promotes proliferation, invasion and migration of cutaneous malignant melanoma via regulating miR-325/MAP3K2. 61
31541886 2019
17
Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. 61
31838403 2019
18
Design, synthesis and molecular mechanisms of novel dual inhibitors of heat shock protein 90/phosphoinositide 3-kinase alpha (Hsp90/PI3Kα) against cutaneous melanoma. 61
30957641 2019
19
Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience. 61
31794964 2019
20
Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma. 61
31778073 2019
21
"Personalized Excision" of Malignant Melanoma-Need for a Paradigm Shift in the Beginning Era of Personalized Medicine. 61
31490196 2019
22
Mechanical stretch promotes tumoricidal M1 polarization via the FAK/NF-κB signaling pathway. 61
31539281 2019
23
Association between the expression of secreted phosphoprotein - related genes and prognosis of human cancer. 61
31849319 2019
24
Tumour-to-tumour Metastasis: Cutaneous Melanoma Metastasizing to Leiomyoma Uteri. 61
31779760 2019
25
Multi-Platform Omics Analysis for Identification of Molecular Characteristics and Therapeutic Targets of Uveal Melanoma. 61
31848373 2019
26
Beta-blockers exert potent anti-tumor effects in cutaneous and uveal melanoma. 61
31588689 2019
27
The co-existence of cutaneous melanoma and urticaria pigmentosa in a patient with Becker's nevus. 61
31803997 2019
28
MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. 61
31568700 2019
29
Overlapping genetic architecture between Parkinson disease and melanoma. 61
31845298 2019
30
Cancer and Sleep Apnea: Cutaneous Melanoma as a Case Study. 61
31339332 2019
31
KIT Mutation Incidence and Pattern of Melanoma in Central Europe. 61
31848942 2019
32
GLT8D1 overexpression as a novel prognostic biomarker in human cutaneous melanoma. 61
31305325 2019
33
Spitzoid cutaneous melanoma is associated with favorable clinicopathological factors and outcome. 61
31012520 2019
34
Malignant transformation of choroidal nevus according to race in 3334 consecutive patients. 61
31755445 2019
35
Melanoma susceptibility variant rs869330 in the MTAP gene is associated with melanoma outcome. 61
30681428 2019
36
Pleural metastasis from auricular melanoma: A brief report. 61
31846216 2019
37
Metabolic flexibility in melanoma: A potential therapeutic target. 61
31362075 2019
38
Interleukin 1 receptor antagonist gene variable number of tandem repeats polymorphism and cutaneous melanoma. 61
31788049 2019
39
Ag@TiO2 Nanoprisms with Highly Efficient Near-Infrared Photothermal Conversion for Melanoma Therapy. 61
31802635 2019
40
Desmoplastic melanoma: The role of pure and mixed subtype in sentinel lymph node biopsy and survival. 61
31804771 2019
41
Use of circulating tumoral DNA to guide treatment for metastatic melanoma. 61
31596166 2019
42
Kinesin family member 18B: A contributor and facilitator in the proliferation and metastasis of cutaneous melanoma. 61
31617652 2019
43
No association between smoking and sentinel lymph node metastasis and survival in cutaneous melanoma. 61
31283036 2019
44
Self-reported naevus density may lead to misclassification of melanoma risk. 61
31833052 2019
45
Gastric 99mTc-Methylene Diphosphonate Accumulation in a Patient With Primary Upper Gastrointestinal Tract Melanoma. 61
31833932 2019
46
Role of angiogenesis in melanoma progression: Update on key angiogenic mechanisms and other associated components. 61
31255774 2019
47
Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. 61
31404607 2019
48
Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma. 61
31359351 2019
49
FARP1 Facilitates Cell Proliferation Through Modulating MAPK Signaling Pathway in Cutaneous Melanoma. 61
31021836 2019
50
Dietary cadmium intake and risk of cutaneous melanoma: An Italian population-based case-control study. 61
31442947 2019

Variations for Skin Melanoma

Cosmic variations for Skin Melanoma:

9 (show top 50) (show all 4660)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM96588509 ZNF451 skin,neck,malignant melanoma,NS c.2114T>G p.I705S 6:57148199-57148199 18
2 COSM143038077 YAP1 skin,neck,malignant melanoma,NS c.1303C>T p.Q435* 11:102229716-102229716 18
3 COSM97229917 XRCC6 skin,scalp,malignant melanoma,NS c.1054C>T p.P352S 22:41650816-41650816 18
4 COSM97227877 XRCC6 skin,scalp,malignant melanoma,NS c.238C>T p.R80* 22:41636155-41636155 18
5 COSM97231271 XRCC6 skin,scalp,malignant melanoma,NS c.1422-1G>T p.? 22:41658251-41658251 18
6 COSM91384800 WT1 skin,scalp,malignant melanoma,NS c.732C>T p.F244= 11:32428534-32428534 18
7 COSM91378277 WT1 skin,scalp,malignant melanoma,NS c.1457G>A p.W486* 11:32389155-32389155 18
8 COSM91367549 WT1 skin,neck,malignant melanoma,NS c.1373G>A p.R458Q 11:32392031-32392031 18
9 COSM91384784 WT1 skin,scalp,malignant melanoma,NS c.742G>A p.D248N 11:32428524-32428524 18
10 COSM91366590 WT1 skin,scalp,malignant melanoma,NS c.1492G>A p.E498K 11:32389120-32389120 18
11 COSM91365011 WT1 skin,scalp,malignant melanoma,NS c.1024G>A p.D342N 11:32400022-32400022 18
12 COSM91365417 WT1 skin,scalp,malignant melanoma,NS c.855G>A p.L285= 11:32427973-32427973 18
13 COSM91377636 WT1 skin,scalp,malignant melanoma,NS c.1041C>T p.P347= 11:32400005-32400005 18
14 COSM85457825 WRN skin,neck,malignant melanoma,NS c.1785C>A p.I595= 8:31090898-31090898 18
15 COSM85455919 WRN skin,scalp,malignant melanoma,NS c.866C>T p.S289L 8:31080893-31080893 18
16 COSM85461009 WRN skin,scalp,malignant melanoma,NS c.3898C>T p.P1300S 8:31157446-31157446 18
17 COSM84687654 VAT1L skin,scalp,malignant melanoma,NS c.503C>T p.A168V 16:77825385-77825385 18
18 COSM84688238 VAT1L skin,scalp,malignant melanoma,NS c.430G>A p.E144K 16:77825312-77825312 18
19 COSM84678743 VAT1L skin,scalp,malignant melanoma,NS c.985G>A p.G329S 16:77884710-77884710 18
20 COSM84680278 VAT1L skin,neck,malignant melanoma,NS c.246C>T p.F82= 16:77816933-77816933 18
21 COSM88838216 USP9X skin,scalp,malignant melanoma,NS c.4006T>C p.F1336L 23:41196279-41196279 18
22 COSM88835558 USP9X skin,scalp,malignant melanoma,NS c.5216C>T p.T1739I 23:41214594-41214594 18
23 COSM89726698 UGT1A9 skin,scalp,malignant melanoma,NS c.856-6491G>A p.? 2:233760543-233760543 18
24 COSM98064686 UGT1A8 skin,scalp,malignant melanoma,NS c.856-6491G>A p.? 2:233760543-233760543 18
25 COSM97950128 UGT1A7 skin,scalp,malignant melanoma,NS c.856-6491G>A p.? 2:233760543-233760543 18
26 COSM86926830 UGT1A6 skin,scalp,malignant melanoma,NS c.862-6491G>A p.? 2:233760543-233760543 18
27 COSM97898735 UGT1A5 skin,scalp,malignant melanoma,NS c.868-6491G>A p.? 2:233760543-233760543 18
28 COSM97877826 UGT1A4 skin,scalp,malignant melanoma,NS c.868-6491G>A p.? 2:233760543-233760543 18
29 COSM117399481 UGT1A3 skin,scalp,malignant melanoma,NS c.868-6491G>A p.? 2:233760543-233760543 18
30 COSM89709626 UGT1A10 skin,scalp,malignant melanoma,NS c.856-6491G>A p.? 2:233760543-233760543 18
31 COSM86958758 UGT1A1 skin,scalp,malignant melanoma,NS c.256G>A p.E86K 2:233760543-233760543 18
32 COSM131092355 TSHR skin,scalp,malignant melanoma,NS c.2043C>T p.F681= 14:81144101-81144101 18
33 COSM131087149 TSHR skin,scalp,malignant melanoma,NS c.291C>T p.F97= 14:81068302-81068302 18
34 COSM87030927 TSC2 skin,scalp,malignant melanoma,NS c.2632C>T p.P878S 16:2075885-2075885 18
35 COSM87047212 TSC2 skin,scalp,malignant melanoma,NS c.2109G>A p.W703* 16:2072252-2072252 18
36 COSM87027807 TSC2 skin,neck,malignant melanoma,NS c.626C>T p.T209I 16:2056222-2056222 18
37 COSM87027367 TSC2 skin,scalp,malignant melanoma,NS c.3347C>T p.A1116V 16:2079619-2079619 18
38 COSM85728352 TSC1 skin,scalp,malignant melanoma,NS c.995C>T p.S332F 9:132911487-132911487 18
39 COSM85722370 TSC1 skin,scalp,malignant melanoma,NS c.248C>T p.A83V 9:132925702-132925702 18
40 COSM94305848 TRRAP skin,neck,malignant melanoma,NS c.4150G>C p.E1384Q 7:98937194-98937194 18
41 COSM94331424 TRRAP skin,scalp,malignant melanoma,NS c.6817A>G p.M2273V 7:98964637-98964637 18
42 COSM94324996 TRRAP skin,scalp,malignant melanoma,NS c.8205G>A p.E2735= 7:98976749-98976749 18
43 COSM94326030 TRRAP skin,scalp,malignant melanoma,NS c.5170C>G p.R1724G 7:98950119-98950119 18
44 COSM94305835 TRRAP skin,neck,malignant melanoma,NS c.3048G>A p.K1016= 7:98927239-98927239 18
45 COSM94313279 TRRAP skin,trunk,malignant melanoma,NS c.3251C>T p.S1084L 7:98930064-98930064 18
46 COSM94305873 TRRAP skin,neck,malignant melanoma,NS c.9803C>T p.P3268L 7:98992171-98992171 18
47 COSM94313428 TRRAP skin,scalp,malignant melanoma,NS c.3310G>A p.E1104K 7:98930123-98930123 18
48 COSM94305826 TRRAP skin,neck,malignant melanoma,NS c.687C>T p.P229= 7:98899475-98899475 18
49 COSM94320883 TRRAP skin,scalp,malignant melanoma,NS c.3407C>T p.P1136L 7:98930646-98930646 18
50 COSM94322324 TRRAP skin,scalp,malignant melanoma,NS c.1568C>T p.P523L 7:98910273-98910273 18

Expression for Skin Melanoma

Search GEO for disease gene expression data for Skin Melanoma.

Pathways for Skin Melanoma

Pathways related to Skin Melanoma according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 TP53 NRAS MMP9 MMP2 MDM2 IGF1R
2
Show member pathways
13.83 TP53 NRAS MDM2 IGF1R FGF2 ERBB2
3
Show member pathways
13.71 TP53 NRAS MMP9 MMP2 MDM2 IGF1R
4
Show member pathways
13.37 TP53 NRAS MMP9 MMP2 FGF2 ERBB2
5
Show member pathways
13.09 TP53 NRAS MDM2 IGF1R FGF2 BRAF
6
Show member pathways
13 TP53 NRAS MDM2 IGF1R FGF2 ERBB2
7
Show member pathways
12.96 TP53 NRAS MDM2 FGF2 CDKN2A CASP3
8
Show member pathways
12.91 TYR NRAS MITF CDKN2B CDKN2A BRAF
9
Show member pathways
12.82 TP53 NRAS MDM2 IGF1R CDKN2A CASP3
10 12.78 TP53 NRAS IGF1R FGF2 ERBB2 CASP3
11
Show member pathways
12.75 TP53 NRAS MDM2 FGF2 ERBB2
12
Show member pathways
12.74 TP53 NRAS ERBB2 CASP3 BRAF
13
Show member pathways
12.72 TP53 NRAS MMP9 MDM2 IGF1R ERBB2
14
Show member pathways
12.67 TP53 NRAS IGF1R FGF2 ERBB2 CDKN2B
15
Show member pathways
12.61 TP53 NRAS MMP2 FGF2 ERBB2
16
Show member pathways
12.59 TP53 NRAS MDM2 IGF1R FGF2 ERBB2
17
Show member pathways
12.52 TP53 NRAS MDM2 ERBB2 CASP3 BRAF
18
Show member pathways
12.51 TP53 NRAS IGF1R ERBB2 BRAF
19 12.49 TP53 NRAS MMP9 MDM2 ERBB2 CDKN2A
20
Show member pathways
12.47 TP53 NRAS MDM2 IGF1R ERBB2 CASP3
21
Show member pathways
12.43 NRAS IGF1R FGF2 ERBB2 BRAF
22
Show member pathways
12.4 TP53 MDM2 CDKN2A CASP3
23 12.39 TP53 MDM2 CDKN2B CDKN2A
24 12.37 TP53 NRAS CDKN2B CDKN2A
25
Show member pathways
12.33 TP53 NRAS MMP9 MMP2 MITF MDM2
26 12.29 TP53 NRAS MDM2 CDKN2B CDKN2A CASP3
27 12.28 TP53 MMP9 MITF MDM2 IGF1R
28
Show member pathways
12.23 TP53 NRAS CASP3 BRAF
29 12.23 TP53 MMP9 MMP2 CASP3 BRAF
30 12.21 TP53 NRAS MDM2 CDKN2B CDKN2A
31
Show member pathways
12.2 TP53 NRAS IGF1R BRAF
32 12.17 TP53 MDM2 CASP3 BRAF
33
Show member pathways
12.16 TP53 NRAS CASP3 BRAF
34
Show member pathways
12.16 TP53 NRAS MDM2 IGF1R ERBB2 CASP3
35 12.16 TP53 NRAS MMP9 MMP2 MDM2 IGF1R
36 12.16 TP53 NRAS MMP9 MMP2 MITF MDM2
37
Show member pathways
12.13 MMP2 MDM2 IGF1R ERBB2
38
Show member pathways
12.13 NRAS MDM2 IGF1R CDKN2B BRAF
39 12.02 TP53 NRAS MDM2 ERBB2 CDKN2A
40 12 TP53 MMP9 MMP2 FGF2
41 11.96 TP53 MDM2 IGF1R CDKN2A BRAF
42 11.89 TP53 NRAS MDM2 IGF1R CDKN2A BRAF
43 11.86 MMP9 MMP2 FGF2
44
Show member pathways
11.83 NRAS CASP3 BRAF
45 11.81 MMP9 MMP2 MITF
46
Show member pathways
11.77 TP53 MDM2 CDKN2A
47 11.75 NRAS IGF1R FGF2 ERBB2 BRAF
48 11.74 TP53 NRAS ERBB2
49 11.74 TP53 MDM2 ERBB2 CDKN2A CASP3
50 11.73 TP53 MMP2 MDM2 CDKN2A

GO Terms for Skin Melanoma

Biological processes related to Skin Melanoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.85 NRAS FGF2 ERBB2 BRAF
2 cytokine-mediated signaling pathway GO:0019221 9.85 TP53 MMP9 MMP2 FGF2 CASP3
3 heart development GO:0007507 9.84 TP53 MDM2 ERBB2 CASP3
4 positive regulation of gene expression GO:0010628 9.8 TP53 MITF MDM2 ERBB2 CDKN2A BRAF
5 response to UV GO:0009411 9.69 TYR TP53 CASP3
6 cellular response to reactive oxygen species GO:0034614 9.65 TP53 MMP9 MMP2
7 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.58 CDKN2B CDKN2A CASP3
8 amyloid fibril formation GO:1990000 9.57 MDM2 CDKN2A
9 negative regulation of fibroblast migration GO:0010764 9.56 FGF2 BRAF
10 wound healing GO:0042060 9.56 TP53 FGF2 ERBB2 CASP3
11 response to antibiotic GO:0046677 9.54 TP53 MDM2 CASP3
12 cellular response to UV-C GO:0071494 9.52 TP53 MDM2
13 negative regulation of apoptotic process GO:0043066 9.5 TP53 MMP9 MITF MDM2 IGF1R CASP3
14 negative regulation of immature T cell proliferation in thymus GO:0033088 9.49 ERBB2 CDKN2A
15 Ras protein signal transduction GO:0007265 9.46 TP53 NRAS FGF2 CDKN2A
16 cellular response to actinomycin D GO:0072717 9.43 TP53 MDM2
17 positive regulation of vascular smooth muscle cell proliferation GO:1904707 8.92 MMP9 MMP2 MDM2 FGF2

Molecular functions related to Skin Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.56 TYR TP53 PMEL MMP9 MDM2 IGF1R
2 disordered domain specific binding GO:0097718 9.33 TP53 MDM2 CDKN2A
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.8 CDKN2B CDKN2A CASP3

Sources for Skin Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....